NY-ESTÉE-LAUDER
Today, The Estée Lauder Companies (NYSE:EL) announced that Justin Boxford has been appointed Global Brand President, Estée Lauder, effective September 1, 2022. Justin succeeds Stéphane de La Faverie, whose promotion to Executive Group President was part of an organizational evolution announced last week. In his new role, Justin is reporting to Stéphane and will continue to serve on the company’s Executive Leadership Team (ELT).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005308/en/
Justin Boxford appointed Global Brand President, Estée Lauder; photo courtesy of Kevin Trageser.
As Global Brand President, Justin will be responsible for driving Estée Lauder’s short- and long-term strategy, including innovation, product development, North America and international growth, consumer marketing and distribution evolution. He will partner closely with members of the global Estée Lauder leadership team to drive the brand’s success for the company and build upon its enduring relevance with consumers worldwide.
“Justin is a dynamic leader who brings to Estée Lauder proven prestige and luxury brand-building expertise, a deep understanding of the global business landscape and extensive background in transforming the online and omnichannel experience,” said Stéphane. “His successful track record of leading teams and growing brand aspiration make him the perfect leader to continue building on the outstanding growth and strength of our flagship brand.”
Justin joins Estée Lauder after almost six years at the helm of La Mer, where he drove outstanding results, boosting net sales to become a top-performing brand for the company, as well as solidifying its leadership in global luxury skin care. Under Justin’s leadership, La Mer has expanded and diversified its product portfolio, building multiple hero engines of growth, and successfully launching products that have strengthened the brand’s luxury architecture, from the new serum-strength The Treatment Lotion to the ultra-luxury Genaissance de la Mer™ regimen. Justin has also led the La Mer team to significantly advance claims, credentialing, and science positioning with breakthrough commercial innovation such as the recent pre-/post-derm campaign for The Concentrate.
Justin led the strategic expansion of La Mer across omnichannel platforms to reach new consumers via highly curated, luxury experiences enabled by digital. La Mer has elevated luxury experience standards on key platforms such as Tmall, and on new platforms in emerging markets.
At the heart of his tenure at La Mer, Justin is also credited with amplifying La Mer’s brand purpose through continued dedication to ocean conservation, illustrated by his implementation of sustainable initiatives into the brand’s business model, and a focus on driving awareness with purpose-led storytelling. Justin is recognized for championing La Mer’s purpose across every part of the business by fostering a culture of equity and inclusion internally, and by delivering value and meaning into the hearts of loyal La Mer consumers.
Since joining the company in 2004, Justin has held several leadership roles around the world and across multiple brands, regions, and channels. Prior to joining La Mer, Justin held the position of Senior Vice President, International, Estée Lauder and TOM FORD BEAUTY, and prior to then, Justin lived in Hong Kong where he led the same brands for the Asia-Pacific (APAC) region. Justin was instrumental in advancing the Estée Lauder brand’s digital, omnichannel, and local relevance strategies internationally, helping to achieve its position as the top skin care brand in the world. He also led the successful launch of TOM FORD BEAUTY internationally, including in China and APAC. Previously, Justin was Vice President, Estée Lauder, Travel Retail.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, LAB Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005308/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
